Q3 2017 Pfenex Inc Earnings Call

9/11/2017 16:30

Conference Call Pfenex Inc

Pfenex Inc Conference call or earnings call will be held on Nov 9, 2017
During the earnings conference call’s session, Pfenex Inc will provide updated information and financial performance report status.
In order to join the earning call, dial the conference’s bridge and key in the PIN code. Contact Pfenex Inc for this information
More and more companies choose to conduct their earnings calls through conference calls and online meetings and it’s important to keep up to date with all relevant information.
Need a conference calls service solution? Try QCONF conferencing today, Sign up now and get 5 free conference calls (no credit card required)
Is this is your first earnings call? Check out Nasdaq guide for how to read an earnings report?
We are a clinical-stage biotechnology company engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Our lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis, marketed by Genentech, Inc., a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases, achieved approximately $4.5 billion in global product sales in 2014. For PF582, we are conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with our collaboration partner, Hospira, Inc., or Hospira, a subsidiary of Pfizer Inc. (collectively with Hospira, "Pfizer"). Pfizer is responsible for manufacturing, clinical studies and commercialization of PF582 globally upon successful receipt of marketing approval. Our next most advanced product candidates are PF530 and PF708.    
Read more Conference Call

Pfenex Inc (PFNX)

10790 Roselle Street, San Diego California 92121, United States